Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.

CONCLUSION: The natural course of SSc-ILD is highly variable. Baseline serum KL-6 is a biomarker potentially useful for predicting FVC decline. PMID: 27481907 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27481907?dopt=Abstract

Source: J Rheumatol - July 31, 2016 Category: Rheumatology Authors: Kuwana M, Shirai Y, Takeuchi T Tags: J Rheumatol Source Type: research

More News: Interstitial Lung Disease | Rheumatology | Scleroderma